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A B S T R A C T
Background: The prognostic impact of worsening renal function (WRF) in acute coronary syndrome (ACS)
patients is not fully understood in Japanese clinical practice, and clinical implication of persistent versus
transient WRF in ACS patients is also unclear.
Methods: With a single hospital-based cohort in the Shinken database 2004–2012 (n = 19,994), we
followed 604 ACS patients who underwent percutaneous coronary intervention (PCI). WRF was deﬁned
as an increase in creatinine during hospitalization of 0.3 mg/dl above admission value. Persistent WRF
was deﬁned as an increase in creatinine during hospitalization of 0.3 mg/dl above admission value and
maintained until discharge, whereas transient WRF was deﬁned as that WRF resolved at hospital
discharge.
Results: WRF occurred in 78 patients (13%), persistent WRF 35 patients (6%) and transient WRF
43 patients (7%). WRF patients were older and had a higher prevalence of chronic kidney disease, history
of myocardial infarction (MI), and ST elevation MI. WRF was associated with elevated inﬂammatory
markers and reduced left ventricular (LV) ejection fraction in acute, chronic phase. Incidence of all-cause
death and major adverse cardiac events (MACE: all-cause death, MI, and target lesion revascularization)
was signiﬁcantly higher in patients with WRF. Moreover, in the WRF group, incidences of all-cause death
and MACE were higher in patients with persistent WRF than those with transient WRF. A multivariate
analysis showed that as well as older age, female gender, and intubation, WRF was an independent
determinant of the all-cause death in ACS patients who underwent PCI.
Conclusions: In conclusion, WRF might have a prognostic impact among Japanese ACS patients who
underwent PCI in association with enhanced inﬂammatory response and LV remodeling. Persistent WRF
might portend increased events, while transient WRF might have association with favorable outcomes
compared with persistent WRF.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The association between cardiovascular disease and chronic
kidney disease (CKD) has been extensively explored all over the
world [1–3] including Japan [4,5]. Similarly it was reported that
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsalso has a prognostic impact and WRF is an independent predictor
of all-cause death from baseline renal function [6,7]. However, the
prognostic impact of WRF in Japanese ACS patients is not fully
understood, and the clinical implication of improvement in renal
function by the time of discharge in ACS patients is also unclear.
Therefore, our primary aim was to explore the prognostic impact of
WRF that developed during hospitalization in Japanese ACS
patients who underwent percutaneous coronary intervention
(PCI), and secondary aim was to explore the clinical implications
of transient versus persistent WRF. reserved.
Table 1
Baseline characteristics of the study population.
Non-WRF (n = 526) WRF (n = 78) p-value
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Study population
We established a single hospital cohort, called the Shinken
database [8–10], which has been including all new patients
visiting the Cardiovascular Institute Hospital, Tokyo, Japan,
since June 2004. It has excluded patients with known active
cancers and travelers. Until March 2013, 19,994 patients had
been enrolled, for whom background characteristics, risk
factors, diagnosis of cardiovascular diseases, blood laboratory
data, physiological test results, medications, and outcomes were
available in the cohort database. Patients were thoroughly
investigated through routine clinical examinations. Among the
Shinken database, all patients diagnosed with ACS [ST elevation
myocardial infarction (STEMI), non-ST elevation myocardial
infarction (NSTEMI), unstable angina (UA)] and who underwent
successful PCI were identiﬁed. The diagnosis of ACS was decided
by cardiologists in our hospital based on deﬁnitions of the
joint committee of the American College of Cardiology (ACC)/
American Heart Association (AHA) [11–13]. The population
in the present study comprised 616 patients who were
hospitalized for ACS and underwent successful PCI at the initial
visit. We deﬁned successful PCI as less than 50% stenosis and
over thrombolysis in myocardial infarction grade 3 ﬂow in
ﬁnal angiography without intervention-related complications
[14]. Patients undergoing regular dialysis treatments were
excluded (n = 12). Finally, a total of 604 patients were examined
in the present study (Fig. 1). The median follow-up period was
1315  903 days.
Renal function
Blood was sampled daily during the ACS hospitalization to
monitor serum creatinine (Cr). Glomerular ﬁltration rate (GFR)
was estimated from gender, age, and Cr, using established
equations for Japanese patients with CKD: GFR = 194  Cr1.094
 age0.287 (if male), GFR = 194  Cr1.094  age0.287  0.739
(if female), CKD was deﬁned as eGFR <60 ml/min/1.73 m2
[15,16]. WRF development was deﬁned as a peak increase in
serum Cr by 0.3 mg/dl from the admission for ACS [7,17,18]. We
deﬁned persistent WRF as an increase in creatinine during
hospitalization of 0.3 mg/dl above admission value and
maintained until discharge, whereas transient WRF as that
WRF resolved at hospital discharge [19,20].Shinken database2004-2012 
(n=19994)
ACS patients underwent  PCI
(n=604)
WRF patients
(n=78)
non-WRF patients
(n=526)
Exclude ACS patients  with  HD
(n=12)
Transient WR F patients 
(n=43)
Persistent WR F patients 
(n=35)
Fig. 1. Patient ﬂow chart of the present study. ACS, acute coronary syndrome; HD,
hemodialysis; PCI, percutaneous coronary intervention; WRF, worsening renal
function.Outcomes
The primary outcome was all-cause death. The secondary
outcome was major adverse cardiac events (MACE), including all-
cause death, myocardial infarction (MI), and target lesion
revascularization (TLR). Major adverse cardiac and cerebrovas-
cular events (MACCE) included MACE and stroke. These out-
comes were ascertained with medical records or reports on
follow-up questionnaires sent to the patients every year.
Outcomes were compared with two groups, WRF group and
non-WRF group. Similarly in sub-analysis, outcomes were
compared with another two groups, persistent WRF group and
transient WRF group.
Statistical analysis
All continuous data were expressed as means  standard
deviation and the mean differences between groups were analyzed
using Student’s t-test. Proportional differences were analyzed using
the x2 test. Group differences in the temporal change in Cr during
the treatment course were assessed using the repeated measures
analysis of variance. Kaplan–Meier curves were used to assess the
unadjusted all-cause death and MACE and the log-rank test was
used to compare these curves. Cox proportional hazards modeling
was used to obtain hazard ratios with adjustment for factors
potentially associated with patient survival and the risk factors for
the WRF development identiﬁed in this study. Sub-analysis was
examined with similar statistic methods between two groups WRF
sustained, or not. A p-value of <0.05 was considered statistically
signiﬁcant. All data were analyzed using SPSS version 19.0 for
Windows (SPSS, Inc., Chicago, IL, USA).
Results
Baseline characteristics
Baseline characteristics of the study population are shown in
Table 1. WRF was observed in 13% (n = 78) of the present
population. The WRF group was signiﬁcantly older (70  12 years
vs 63  12 years, p < 0.001) and had higher prevalence of CKD (51% vsAge (years) 63  12 70  12 <0.001
BMI (kg/m2) 25  4 24  4 0.498
Male gender, n (%) 460 (87) 64 (82) 0.189
Diabetes, n (%) 158 (30) 25 (32) 0.718
Hypertension, n (%) 312 (59) 51 (65) 0.307
Dyslipidemia, n (%) 317 (60) 44 (56) 0.517
CKD, n (%) 127 (24) 40 (51) <0.001
Smoking, n (%) 236 (45) 28 (36) 0.136
Family history, n (%) 77 (15) 8 (10) 0.299
History of MI, n (%) 25 (5) 8 (10) 0.046
History of PCI, n (%) 30 (5) 5 (6) 0.803
History of CABG, n (%) 7 (1) 1 (1) 0.972
LMT disease, n (%) 14 (3) 4 (5) 0.232
Multi-vessel disease, n (%) 133 (25) 26 (33) 0.132
STEMI, n (%) 238 (45) 45 (58) 0.040
Killip more than 2, n (%) 76 (14) 35 (45) <0.001
IABP, n (%) 38 (7) 24 (31) <0.001
PCPS, n (%) 4 (1) 6 (8) <0.001
Intubation, n (%) 13 (2) 10 (13) <0.001
WRF, worsening renal function; BMI, body mass index; CKD, chronic kidney
disease; MI, myocardial ischemia; PCI, percutaneous coronary intervention;
CABG, coronary artery bypass graft; LMT, left main trunk; STEMI, ST elevation
myocardial ischemia; IABP, intra-aortic balloon pumping; PCPS, percutaneous
cardiopulmonary support.
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(58% vs 45%, p = 0.040) than the non-WRF group. There was no
signiﬁcant difference in gender, body mass index, prevalence of
classic coronary risk factors, ACS culprit lesion, and past therapeutic
history including PCI and coronary artery bypass graft.
Clinical parameters
Clinical parameters of the study population are shown in
Table 2. Blood pressure, heart rate at admission, and the volume of
contrast medium (WRF: 220  101 ml vs non-WRF: 210  85 ml, p =
0.456) at PCI was similar in both groups. Whereas, eGFR (61.1  25.8 ml/
min/1.73 m2 vs 72.7  19.8 ml/min/1.73 m2, p < 0.001), left ventricular
(LV) ejection fraction at admission (51  16% vs 60  12%, p < 0.001) and
one year after discharge (57  13% vs 62  11%, p = 0.004) were lower in
patients with WRF than non-WRF. In addition, the WRF group had higher
blood glucose level (167  78 mg/dl vs 145  60 mg/dl, p = 0.023),
baseline and peak white blood cell (WBC) count (baseline: 10,891 
4701/ml vs 8574  3414/ml, p < 0.001; peak: 14,336  6133/ml vs 10,654
 3619/ml, p < 0.001), baseline and peak C-reactive protein (CRP)
(baseline: 2.2  4.2 mg/dl vs 1.0  2.8 mg/dl, p = 0.024; peak: 11.9  9.0
mg/dl vs 4.9  5.6 mg/dl, p < 0.001), and peak creatine kinase (CK) (2428
 2891 IU/L vs 1132  1681 IU/L, p < 0.001) than the non-WRF group.
Medications at discharge
Medication use at discharge is presented in Table 2. WRF
patients were prescribed more diuretics (33% vs 9%, p < 0.001)
and fewer statins (59% vs 71%, p = 0.011) than non-WRF patients
at discharge. Prescription rate of dual antiplatelet therapy
(DAPT), beta-blocker, and angiotensin-converting enzyme inhib-
itor (ACEI)/angiotensin receptor blocker (ARB) was similar in
both groups.
WRF and clinical outcomes
During the follow-up period, there were 32 deaths (cardiac
death = 15, non-cardiac death = 17, in-hospital death = 4),Table 2
Clinical parameters and medication at discharge of the study population.
Non-WRF
(n = 526)
WRF
(n = 78)
p-value
Systolic blood pressure (mmHg) 136  25 138  34 0.498
Diastolic blood pressure (mmHg) 79  16 80  19 0.411
Heart rate (bpm) 80  50 80  20 0.997
LVEF at admission (%) 60  12 51  16 <0.001
LVEF one year after discharge (%) 62  11 57  13 0.004
eGFR (ml/min/1.73 m2) 72.7  19.8 61.1  25.8 <0.001
Contrast medium (ml) 220  101 210  85 0.456
Glucose (mg/dl) 145  60 167  78 0.023
Baseline WBC (/m) 8574  3414 10,891  4701 <0.001
Peak WBC (/m) 10,654  3619 14,336  6133 <0.001
Baseline CRP (mg/dl) 1.0  2.8 2.2  4.2 0.024
Peak CRP (mg/dl) 4.9  5.6 11.9  9.0 <0.001
Peak CK (IU/L) 1132  1681 2428  2891 <0.001
DAPT, n (%) 500 (96) 71 (95) 0.144
OAC, n (%) 37 (7) 6 (8) 0.833
Statin, n (%) 372 (71) 44 (59) 0.011
Beta-blocker, n (%) 223 (43) 41 (55) 0.091
ACEI/ARB, n (%) 345 (66) 51 (68) 0.972
CCB, n (%) 158 (30) 25 (33) 0.718
Vasodilator, n (%) 132 (25) 27 (36) 0.075
Diuretic, n (%) 49 (9) 25 (33) <0.001
WRF, worsening renal function; LVEF, left ventricular ejection fraction; eGFR,
estimated glomerular ﬁltration rate; WBC, white blood cell; CRP, C-reactive
protein; CK, creatine kinase; DAPT, dual antiplatelet therapy; OAC, oral
anticoagulant; ACEI, angiotensin-converting enzyme inhibitor; ARB, angioten-
sin receptor blocker; CCB, calcium channel blocker.140 MACE, 149 MACCE, 22 MI, 102 TLR, and 37 heart failure
admissions among all 604 cohort members. All-cause death,
cardiac death, non-cardiac death, MACE, MACCE, MI, and heart
failure admission were more commonly observed in WRF group
than non-WRF group, while with regard to TLR, there was no
signiﬁcant difference between the two groups (Table 3).
WRF was associated with higher incidence of all-cause death
(Fig. 2A) and MACE (Fig. 2B) during the observation period as
revealed by Kaplan–Meier curves and log-rank test. Univariate Cox
proportional hazards model analysis for all-cause death showed
that WRF, age, body mass index, female gender, presence of CKD,
LV ejection fraction at admission, blood glucose, the level of
inﬂammatory biomarkers (WBC count, serum CRP level at hospital
admission), peak CK, diuretics at discharge, higher Killip level (2),
and frequency of intra-aortic balloon pumping/percutaneous
cardiopulmonary support, intubation were associated with sur-
vival (Table 4). Multivariate Cox proportional hazard model
analysis revealed that, as well as older age, female gender, and
intubation, WRF was an independent determinant of all-cause
death (Table 4).
Sub-analysis
In sub-analysis, we analyzed outcomes of transient and
persistent WRF patients. Persistent WRF occurred in 35 patients
(6%) and transient WRF occurred in 43 patients (7%). There were
19 deaths (in-hospital deaths = 3), 30 MACE, 30 MACCE, 6 MI,
13 TLR, and 16 heart failure admissions. All-cause death, cardiac
death, MACE, and MACCE were more commonly observed in
persistent WRF group than transient WRF group, while there
was no signiﬁcant difference between the two groups with
regard to non-cardiac death, MI, TLR, and heart failure admission
(Table 3). Incidences of all-cause death (Fig. 3A) and MACE
(Fig. 3B) were higher in patients with persistent WRF than those
with transient WRF. Patients with transient WRF had worse
outcomes than patients with stable renal function; moreover
patients with persistent WRF had worst outcomes of three
groups compared with stable renal function (Fig. 4). In addition,
we investigated two periods and an increase in Cr duringTable 3
Clinical outcomes of acute coronary syndrome patients.
Non-WRF
(n = 526)
WRF
(n = 78)
p-value
All-cause death 13 (2) 19 (24) <0.001
Cardiac death 4 (0.7) 11 (14) <0.001
Non-cardiac death 9 (2) 8 (10) <0.001
In-hospital death 1 (0.2) 3 (4) <0.001
MACE 110 (21) 30 (38) 0.001
MACCE 119 (23) 30 (38) 0.003
MI 16 (3) 6 (8) 0.035
TLR 89 (17) 13 (17) 0.784
Heart failure 21 (4) 16 (20) <0.001
Transient
WRF (n = 43)
Persistent
WRF (n = 35)
p-value
All-cause death 6 (14) 13 (37) 0.028
Cardiac death 2 (5) 9 (26) 0.011
Non-cardiac death 4 (9) 4 (11) 0.681
In-hospital death 1 (2) 2 (6) 0.421
MACE 10 (23) 20 (57) 0.013
MACCE 10 (23) 20 (57) 0.013
MI 2 (5) 4 (11) 0.265
TLR 7 (16) 6 (17) 0.854
Heart failure 6 (14) 10 (29) 0.123
WRF, worsening renal function; MI, myocardial infarction; TLR, target lesion
revascularization; MACE, major adverse cardiac events; MACCE, major adverse
cardiac and cerebrovascular events; Data are expressed as counts (percentage).
Fig. 2. (A) Kaplan–Meier curves for all-cause death-free survival rate in study population. (B) Kaplan–Meier curves for MACE-free survival rate in study population. MACE,
major adverse cardiac events; WRF, worsening renal function.
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and another was from peak Cr until discharge. The duration from
admission until peak Cr was shorter in transient group than
persistent group (4.8  6.3 days vs 11.8  11.7 days, p = 0.001).
Whereas, the duration from peak Cr until discharge was longer in
the transient group than the persistent group (12.8  13.7 days vs
6.2  7.9 days, p = 0.016). An increase in Cr during hospitalization
was lower in the transient group than the persistent group (0.65 
0.51 mg/dl vs 0.91  0.72 mg/dl, p = 0.066). Persistent WRF
patients had higher peak Cr level at delayed phase in hospitaliza-
tion than transient WRF patients.Table 4
Univariate and multivariate analysis for predictors of all-cause mortality.
Univariate Hazard ratio 95% CI p-value
WRF 10.308 5.090–20.877 <0.001
Age 1.113 1.077–1.150 <0.001
BMI 0.816 0.723–0.922 0.001
Male gender 0.317 0.150–0.669 0.003
CKD 8.12 3.748–17.594 <0.001
LVEF 0.946 0.925–0.968 <0.001
Glucose 1.006 1.001–1.010 0.008
WBC per 1000 1.097 1.012–1.189 0.024
CRP 1.161 1.096–1.229 <0.001
Peak CK per 1000 1.157 1.008–1.327 0.038
Diuretics at discharge 4.964 2.422–10.173 <0.001
Killip more than 2 2.998 1.358–6.618 0.007
IABP/PCPS 4.216 1.995–8.907 <0.001
Intubation 12.414 4.605–33.466 <0.001
Multivariate Hazard ratio 95% CI p-value
WRF 11.663 4.606–29.529 <0.001
Age 1.088 1.044–1.133 <0.001
Male gender 0.337 0.129–0.880 0.026
Intubation 11.725 2.862–48.034 0.001
CI, conﬁdence interval; WRF, worsening renal function; CKD, chronic kidney
disease; BMI, body mass index; WBC, white blood cell; CRP, C-reactive protein;
CK, creatine kinase; LVEF, left ventricular ejection fraction; IABP, intra-aortic
balloon pumping; PCPS, percutaneous cardiopulmonary support.Discussion
The present study showed that WRF was related to a poor
clinical outcome in Japanese ACS patients who underwent PCI.
Poor prognosis was independent from baseline renal function, and
did not appear to be related to the initial clinical presentation. The
main ﬁndings of the present study were the following.
(1) WRF was observed in 13% of ACS patients who underwent
PCI.
(2) WRF patients were older and had a higher prevalence of CKD
and LV dysfunction. WRF was associated with higher inﬂam-
matory markers such as WBC count and CRP, and were
prescribed more diuretics and less statins at discharge than the
non-WRF group.
(3) As well as older age, female gender, and intubation, presence of
WRF was an independent predictor of all-cause death.
(4) Incidences of all-cause death and MACE were higher in patients
with persistent WRF than those with transient WRF. Persistent
WRF patients had higher peak Cr level at delayed phase in
hospitalization than transient WRF patients.
AlFaleh et al. reported that WRF was a powerful predictor for in-
hospital death and cardiovascular complications in ACS patients
[6]. Amin et al. also reported that there was a linear relationship
between the extent of WRF and the risk of long-term mortality
[7]. Even a small decline in renal function has been reported to be
associated with increased mortality, length of hospital stay, and cost
in hospitalized patients [21]. WRF was observed in 13% of ACS
patients who underwent PCI in this study. A recent study in Saudi
Arabia showed that approximately 6% of ACS patients had WRF within
7 days of hospitalization [6]. In the present study, the incidence of
WRF in ACS patients appeared to be relatively high. Compared with
the study in Saudi Arabia, of the factors that were associated with
WRF, such as age, prevalence of CKD, and STEMI, the severity of CKD
on admission was higher in our study. It might affect the difference. In
addition, the deﬁnition of WRF might affect the difference of the
incidence of WRF [22,18]. In fact, another recent study which used
Fig. 3. (A) Kaplan–Meier curves for all-cause death-free survival rate in WRF group. (B) Kaplan–Meier curves for MACE-free survival rate in WRF group. MACE, major adverse
cardiac events; WRF, worsening renal function.
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patients had WRF [7], which was equivalent with the present study.
In this study, WRF patients were older and had baseline renal
insufﬁciency, and LV dysfunction. The severity of CKD on
admission was higher in WRF patients than in non-WRF patients.
WRF was associated with higher inﬂammatory markers, such as
WBC count, serum CRP level, and were prescribed more diuretics
and fewer statins at hospital discharge than the non-WRF group. In
contrast, there was no signiﬁcant difference in gender, body mass
index, prevalence of classic coronary risk factors, the volume ofFig. 4. Kaplan–Meier curves for all-cause death-free survival rate in 3 groups. WRF,
worsening renal function.contrast medium at PCI, and prescription of DAPT, beta-blocker,
and ACE-I/ARB. Similar to the present study, older age, CKD and LV
dysfunction were associated with WRF in Western countries
[6,7]. The volume of contrast medium was not signiﬁcantly
different between patients with WRF and without WRF. Anzai et al.
previously reported that acute kidney injury (AKI) after STEMI was
not associated with the volume of contrast medium [23]. Goldberg
et al. also reported that transient and persistent AKI after acute
myocardial infarction was not associated with the volume of
contrast medium [24]. On the other hand, other factors such as
inﬂammation and neurohormonal activation induced by ACS
might aggravate the renal function and result in poor clinical
outcomes.
Multivariate analysis showed that the presence of WRF was an
independent predictor of all-cause death, cardiac death, and non-
cardiac death. Several potential mechanisms have been proposed
to explain the association between WRF and poor prognosis in ACS
patients. One mechanism was inﬂammatory factors, and another
mechanism was neurohormonal factors. Both factors might be
associated with LV remodeling. Devarajan et al. reported that
systemic inﬂammation was the factor of acute renal dysfunction.
Ischemia induces renal endothelial dysfunction followed by
intense renal vasoconstriction, overexpression of adhesion mole-
cules, acceleration of inﬂammatory cells migration, and microvas-
cular congestion. Such inﬂammatory cascade can be markedly
augmented by the generation of pro-inﬂammatory and chemotac-
tic cytokines, released by inﬂammatory cells [25]. These ﬁndings
indicate that activated systemic inﬂammation after ACS, reﬂected
by higher peripheral WBC count, and serum CRP level in the
present study, might be a key player in the induction and even
enhancement of WRF. In fact, the relationship between AKI and
inﬂammatory markers was reported previously [23]. The vulnera-
ble myocardium, which consists of necrotic tissue and inﬂamma-
tory cells, is susceptible to wall stress, resulting in infarct
expansion [26]. Systemic inﬂammation relates to LV remodeling,
therefore, inﬂammation by WRF at ACS may contribute to the poor
outcomes at chronic phase. There is the possibility that anti-
inﬂammatory drugs such as statins might prevent WRF by
controlling inﬂammatory cascade. In our study, WRF patients
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There might be a clinical problem for long-term prognosis in our
clinical setting. It was usual practice that there was hesitation to
prescribe statins to patients with renal dysfunction, but our recent
study reported that statin therapy was associated with reduced all-
cause mortality in patients with renal dysfunction and coronary
artery disease after PCI [16]. In addition to inﬂammatory factors,
neurohormonal factors in association with LV remodeling,
including renin-angiotensin-aldosterone systems and the sympa-
thetic nervous systems, are known to be activated after ACS and to
be involved in the cardiorenal syndrome [27,28]. Importantly,
among ACS patients developing WRF, beta-blockers and ACE-I/
ARBs might improve long-term prognosis by attenuating neuro-
hormonal activation. Amin et al. reported that ACS patients
developing WRF who used ACE-I/ARBs had a 37% lower hazard for
4-year mortality [7]. WRF following ACS might possibly serve as a
marker of cardiac disease severity. On the other hand, WRF might
be an active participant in further cardiovascular injury through
the activation of neurohormonal- and immune-mediated path-
ways. Aggressive use of conventional cardiovascular therapies or
new therapeutic strategies might be beneﬁcial for patients with
coexistent WRF and ACS.
In sub-analysis, incidence of all-cause death and MACE were
higher in patients with persistent WRF than those with transient
WRF. In particular, with regard to all-cause death, patients with
transient WRF had worse outcome than patients with stable renal
function, and patients with persistent WRF had worst outcome of
these three groups. Latchamsetty et al. reported that the return to
baseline renal function during hospitalization does not appear to
protect from cardiovascular risk in ACS patients [19]. While,
Aronson et al. reported that persistent WRF portended increased
mortality, transient WRF appeared to be associated with a better
outcome as compared with persistent WRF as well as non-WRF in
acute decompensated heart failure [20]. Therefore, the prognostic
impact of persistent and transient WRF in ACS patients is still
controversial. In our study, recovery of renal function after WRF
had important prognostic implications. Furthermore, persistent
WRF patients had higher peak Cr level at delayed phase in
hospitalization than transient WRF. Peak Cr level and the time
when WRF occurred might be associated with poorer outcomes.
We will further analyze in the next study about this point. Our
study was of a small sample size, so we could not conclude it, but
we should prevent WRF, and optimize renal protection after WRF.
Importantly many of the factors that promote WRF such as
neurohormonal factors, inﬂammatory factors, diuretic use and
dosing [29], and hemodynamic state [30] are potentially reversible,
so initiation of anti-neurohormonal, and anti-inﬂammatory drugs
such as beta-blockers, ACE-I/ARBs, statins, or reduction of diuretics
dose or stabilization of hemodynamic state may prevent persistent
WRF. Although CKD could not be treated after the ACS, an early
therapeutic intervention to prevent WRF might be crucial in
improving the clinical outcomes of ACS patients undergoing PCI.
Study limitations
The present study has several limitations. First, this study is
based on a single-center cohort, so it does not include a large
sample of ACS patients. Our database has been including all new
inpatients and outpatients visiting our hospital. Half of the patients
are not diagnosed with cardiovascular diseases, and our hospital is
located in a place where there is a small population at night time.
So, the prevalence of ACS is lower than expected. Since our hospital
is a single-department cardiovascular facility, ACS patients with
unstable hemodynamic state, such as cardiopulmonary arrest
and cardiogenic shock are seldom transferred to our hospital.
Therefore, the number of ACS patients with unstable and severehemodyamic state is supposed to be smaller than expected. A
multi-center cohort with a large sample is required to conﬁrm our
results. Second, we have no data about renovascular events such as
induction of dialysis because our hospital is a single-department
cardiovascular facility. It is an important factor about renovascular
events when the study about renal function is analyzed. Third, we
established a comprehensive database with demographic, physio-
logical, and clinical variables that we adjusted for in the analyses.
However, as with all observational studies, it is possible that
unmeasured confounders may inﬂuence the results. In particular,
we have no data available about unsuccessful PCI, which is
supposed to inﬂuence the outcomes. Lastly, there are various
deﬁnitions of WRF or AKI and different deﬁnitions could alter the
results. In the present study, we used WRF deﬁned as an absolute
increase in serum Cr of 0.3 mg/dl, because there are several
studies demonstrating that this level of Cr increase has an impact
on the outcomes and because this cut-off level is endorsed by the
Acute Kidney Injury Network.
Conclusion
WRF had a short-term and long-term prognostic impact in
Japanese ACS patients undergoing PCI in association with LV
remodeling and enhanced inﬂammatory response. In WRF
patients, persistent WRF had further clinical impacts than
transient WRF.
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